OCX stock is plunging Wednesday. Why? The more than 30% drop occurred after OncoCyte Corporation (NYSE:OCX) provided a mid-year update, which principally discussed the company’s CLIA Validation study of DetermaVu™.
Here’s what we know.
OCX Stock Drops More Than 30%Based in Alameda, California, OncoCyte Corporation is a company that focuses on developing novel, non-invasive tests used to detect cancer. The company focuses on detecting cancer early on, as this can improve the patient’s quality of life and reduce the cost of care. Since late April, OncoCyte has been conducting a liquid biopsy test ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.